Johns Hopkins Tests Deliberate Pacing Trick to Rescue Failing Hearts
A pilot trial explores whether intentionally inducing brief daily dyssynchrony via pacemaker can retrain failing heart muscle in humans.
Cardiovascular disease prevention, blood pressure, cholesterol, and heart function
675 articles
A pilot trial explores whether intentionally inducing brief daily dyssynchrony via pacemaker can retrain failing heart muscle in humans.
Researchers discover that salt-triggered aortic dissection hinges on a receptor that guards mitochondrial energy metabolism in vessel walls.
Myqorzo (aficamten) wins FDA approval for symptomatic obstructive HCM, offering a novel cardiac myosin inhibitor option for patients.
Pfizer's landmark trial examines whether tafamidis can safely treat transthyretin amyloid cardiomyopathy, a progressive and often fatal heart condition.
A Cochrane review of 21 RCTs finds remote pharmacist care may improve adherence and lower blood pressure in NCD patients.
New JAMA research ties widely used food additives to elevated blood pressure and cardiovascular disease risk.
Phase 3 trial pits lerodalcibep against inclisiran to determine which PCSK9 inhibitor best cuts LDL in cardiovascular high-risk patients.
A Phase 2 trial tests once-daily oral resmetirom (MGL-3196) against placebo to reduce LDL-C in patients with inherited high cholesterol.
A completed Phase 3 trial evaluates obicetrapib added to maximum lipid-lowering therapy in patients with familial hypercholesterolemia and ASCVD.
A mass spectrometry apolipoprotein panel predicts cardiovascular events and identifies who gains the most from PCSK9 inhibitor therapy.
A 94,000-person study finds high remnant cholesterol raises heart disease risk 45% — yet triggers far less statin prescribing than high LDL.
A newly discovered mitochondrial protein boosts cardiac glucose burning and dramatically reduces heart injury after ischemia-reperfusion.